Not time to abandon use of local vaginal hormone therapies

JoAnn V. Pinkerton, Andrew M. Kaunitz, JoAnn E. Manson
In: Menopause · 2018 · vol. 25(8) , pp. 855–858 · doi:10.1097/gme.0000000000001142 · PMID:29894370 · W2807980208
editorial OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-02 ⓘ

This review examines the current evidence on local vaginal hormone therapies, concluding that their established safety and efficacy profile supports continued use for managing genitourinary syndrome of menopause.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Pinkerton, JoAnn V. MD, FACOG, NCMP; Kaunitz, Andrew M. MD, FACOG, NCMP; Manson, JoAnn E. MD, DrPH, FACP, NCMP

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (20)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-09-16T06:28:21.314993+00:00
License: CC0 · commercial use OK